Shares of Crispr Therapeutics AG (NASDAQ:CRSP) shot up 0% during trading on Tuesday . The stock traded as high as $49.72 and last traded at $48.34. 1,893,100 shares traded hands during trading, an increase of 79% from the average session volume of 1,060,236 shares. The stock had previously closed at $48.34.
Several research firms have commented on CRSP. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Citigroup increased their price target on shares of Crispr Therapeutics from $20.00 to $51.00 and gave the company a “neutral” rating in a research report on Wednesday. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. Finally, SunTrust Banks raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Crispr Therapeutics currently has an average rating of “Buy” and a consensus price target of $28.45.
In related news, insider Tyler Dylan-Hyde sold 15,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $18.90, for a total value of $283,500.00. Following the completion of the transaction, the insider now directly owns 130,204 shares of the company’s stock, valued at approximately $2,460,855.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $18.98, for a total transaction of $21,114,225.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,499,287 shares of company stock valued at $30,340,218. Insiders own 39.98% of the company’s stock.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.